Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial

Michelle O'Donoghue, Ruchira Glaser, Philip Aylward, Matthew Cavender, Adam Crisp, Keith Fox, Ian Laws, Jose Lopez-Sendon, P Steg, Pierre Theroux, Marc Sabatine, David Morrow

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science